SCOHIA PHARMA Announces Presentation of SCO-006 Research Findings and Development Update at Inositol Phosphate and Pyrophosphate Signalling 2026

SCOHIA PHARMA, Inc. (Fujisawa, Kanagawa, Japan; "SCOHIA") today announced that it presented research findings on SCO-006, an inositol hexakisphosphate kinase (IP6K) inhibitor being developed for the treatment of hyperphosphatemia, and provided an update on its development progress at "Inositol Phosphate and Pyrophosphate Signalling 2026," held in York, UK, from October 13 to 15, 2026.

The presentation clarified that the compound previously reported in scientific publications as SC-919 is SCO-006 and outlined the goal of initiating a first-in-human (FIH) clinical trial in 2027. SCOHIA remains committed to advancing the research and development of SCO-006 toward this goal.

Conference Presentation Details
Conference : Inositol Phosphate and Pyrophosphate Signalling 2026
Date & Location : October 13-15, 2026, York, UK
Presentation Format / Number : Flash Poster (P011)
Title : Pharmacological inhibition of IP6K by SCO-006 regulates XPR1-dependent phosphate export and systemic phosphate homeostasis

Related Information
Conference Information: https://www.eventsforce.net/biochemsoc/frontend/reg/absViewDocumentFE.csp?documentID=8802&eventID=260
Related Publication: The enzymatic activity of inositol hexakisphosphate kinase controls circulating phosphate in mammals
Nature Communications (2021), https://doi.org/10.1038/s41467-021-24934-8

■ About SCOHIA PHARMA, Inc.
SCOHIA PHARMA is a discovery-driven biotechnology company with deep expertise in endocrine, cardiovascular, renal, and metabolic diseases. The Company is committed to the discovery and development of first-in-class and best-in-class therapeutics to address high unmet medical needs. By integrating advanced small molecule and peptide drug discovery technologies with pathophysiology-driven insights, SCOHIA PHARMA strives to deliver innovative medicines. For more information, please visit https://www.scohia.com/eng.